Alterola Biotech, Inc.

Equities

ABTI

US02152V1035

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 14:30:00 10/05/2024 BST			5-day change	1st Jan Change
0.0033 ^USD	-10.81%		-10.81%	-8.33%

02-20	Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Alterola Biotech, Inc. Announces Removal of Lalit Kumar Verma as A Director

December 10, 2021 at 06:11 pm

Alterola Biotech, Inc. announced that the shareholders executed a written consent under Nevada law with the requisite number of votes to remove Lalit Kumar Verma as a Director of the Company, Effective December 8, 2021.

Latest news about Alterola Biotech, Inc.

Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-20	CI
Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-21	CI
Alterola Biotech, Inc. Announces Executive Changes	17/10/23	CI
Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	15/08/23	CI
Alterola Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	10/07/23	CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt	09/07/23	CI
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23	CI
Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	21/11/22	CI
Alterola Biotech, Inc. Executive Changes	07/10/22	CI
Alterola Biotech, Inc. Appoints Terry Rafih as A Member of Board of Directors	07/10/22	CI
Bright Green Corporation completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) from Phytotherapeutix Holdings Limited, Equipped 4 Holdings Limited and T.P.R. Global Service Srl.	03/10/22	CI
Sector Update: Health Care Stocks Rebound Slightly in Late Trade, Pare Losses	30/08/22	MT
Sector Update: Health Care Stocks Dropping Tuesday Afternoon	30/08/22	MT
Bright Green Corporation has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) from Phytotherapeutix Holdings Limited, Equipped 4 Holdings Limited and T.P.R. Global Service Srl for $4 million.	29/08/22	CI
Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	18/08/22	CI
Alterola Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	10/06/22	CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt	09/06/22	CI
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	01/03/22	CI
Alterola Biotech, Inc. Announces Removal of Lalit Kumar Verma as A Director	10/12/21	CI
Alterola Biotech, Inc. completed the acquisition of the assets from C2 Wellness Corporation.	01/12/21	CI
Alterola Biotech, Inc. signed an agreement to acquire the assets from C2 Wellness Corporation for $6.4 million.	15/11/21	CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt	18/10/21	CI
Alterola Biotech : Board Replaces Outgoing CFO Larson Elsmore With Timothy Rogers as Interim CFO	05/10/21	MT
Alterola Biotech, Inc. Announces Executive Changes	05/10/21	CI
Alterola Biotech, Inc. Announces Executive Changes	05/10/21	CI

Chart Alterola Biotech, Inc.

Duration

Period

More charts

Company Profile

Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALTEROLA BIOTECH, INC.	-8.33%	4.56M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B

Bio Therapeutic Drugs